Cholesterol absorption blockade with ezetimibe

Current Drug Targets - Cardiovascular and Haematological Disorders

Volumn 5, Issue 6, 2005, Pages 455-462

  Toth, Peter P ^a,b,c   Davidson, Michael H ^a,b,c  

^a Sterling Rock Falls Clinic ^*  (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

^c RUSH MEDICAL COLLEGE   (United States)

Author keywords

2 azetidinone; Atherosclerosis; Cholesterol; Coronary artery disease; Ezetimibe; Familial hypercholesterolemia; Lipoprotein; Phytosterol; Sitosterolemia

Indexed keywords

ANTIFUNGAL AGENT; ATORVASTATIN; C REACTIVE PROTEIN; CYCLOSPORIN; DIGOXIN; ETHINYLESTRADIOL; EZETIMIBE; FENOFIBRATE; FLUINDOSTATIN; GEMFIBROZIL; GLIPIZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MACROLIDE; MEVINOLIN; PLACEBO; PRAVASTATIN; SIMVASTATIN; WARFARIN;

BONE MARROW TOXICITY; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL DIET; CHOLESTEROL METABOLISM; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG MEGADOSE; DRUG POTENTIATION; DYSLIPIDEMIA; FAMILIAL HYPERCHOLESTEROLEMIA; FATALITY; GASTROINTESTINAL ABSORPTION; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; HYPERLIPIDEMIA; INCIDENCE; INTESTINE CELL; INTRACELLULAR SPACE; LIFESTYLE; LIVER TOXICITY; MONOTHERAPY; MORTALITY; MUSCLE DISEASE; MYALGIA; MYOSITIS; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PHARMACOLOGICAL BLOCKING; REVIEW; RHABDOMYOLYSIS; RISK FACTOR; SIDE EFFECT; STROKE; TRANSAMINITIS;

ANTICHOLESTEREMIC AGENTS; AZETIDINES; CHOLESTEROL; CLINICAL TRIALS; HUMANS; INTESTINAL ABSORPTION; MODELS, BIOLOGICAL; TREATMENT OUTCOME;

EID: 29444459911     PISSN: 15680061     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800605774962086     Document Type: Review

References (52)

1. Genest, J., Forblich, J., Fodor, G., McPherson, R. Working Group on Hypercholesterolemia and other Dyslipidemias. Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update. CMAJ, 2003, 169, 921-4.
2. Second Joint Task Force of European and other Societies on Coronary Prevention. Prevention of coronary hearts disease in clinical practice. Eur. Heart J., 1998, 19, 1434-1503.
3. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA, 2001, 285, 2486-2497.
4. Grundy, S.M., Cleeman, J.I., Merz, C.N., Brewer, H.B. Jr., Clark, L.T., Hunninghake, D.B., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation, 2004, 110(2), 227-39.
5. Toth, P.P. Clinician update: HDL and Cardiovascular Risk. Circulation, 2004, 109, 1809-1812.
6. Toth, P.P. High-density lipoprotein: epidemiology, metabolism, and antiatherogenic effects. Disease-a-Month, 2001; 47, 369-416.
7. Toth, P.P. Reverse cholesterol transport: high-density lipoprotein's magnificent mile. Curr. Atheroscler. Rep., 2003, 5, 386-393.
8. American Diabetes Association. Dyslipidemia management in adults with diabetes. Diabetes Care, 2004, 27, S68-S71.
9. Mosca, L., Appel, L.J., Benjamin, E.J., Berra, K., Chandra-Strobos, N., Fabunmi, R.P., et al. Evidence-based guidelines for cardiovascular disease prevention in women. Circulation, 2004, 109, 672-693.
10. Hoerger, T.J., Bala, M.V., Bray, J.W., Wilcosky, T.C., Larosa, J. Treatment patterns and distribution of low-density lipoprotein cholesterol levels in treatment-eligible United States adults. Am. J. Cardiol., 1998, 82(1), 61-5.
11. Pearson, T.A., Laurora, I., Chu, H., Kafonek, S. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch. Intern. Med., 2000, 160(4), 459-67.
12. Jacobson, T.A., Griffiths, G.G, Varas, C., Gause, D., Sung, J.C., Ballantyne, C.M. Impact of evidence-based "clinical judgment" on the number of American adults requiring lipid-lowering therapy based on updated NHANES III data. National Health and Nutrition Examination Survey. Arch. Intern. Med., 2000, 160, 1361-1369.
13. Cannon, C.P., Braunwald, E., McCabe, C.H., Rader, D.J., Rouleau, J.L., Belder, R. et al. Comparison of intensive and moderate lipid lowering with statins after acute coronary syndromes. N. Engl. J. Med., 2004, 350, 1495-1504.
14. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet, 2002, 360, 7-22.
15. Nissen, S.E., Tuzcu, E.M., Schoenhagen, P., Brown B.G., Ganz, P., Vogel, R.A., et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA, 2004, 291, 1071-1080.
16. Denke, M.A. Combination Therapy. J. Manag. Care Pharm., 2003, 9(Suppl. 1), 17-9.
17. Thompson, G.R., Grundy, S.M. History and development of plant sterol and stanol esters for cholesterol-lowering purposes. Am. J. Cardiol., 2005, 96, 3D-9D.
18. Altmann, S.W., Davis, H.R., Jr., Zhu, L.J., Yao, X., Hoos, L.M., Tetzloff, G., et al. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science, 2004, 303, 1201-1204.
19. Wang, J., Joy, T., Mymin, D., Frihlich, J., Hegele, R.A. Phenotypic heterogeneity of sitosterolemia. J. Lipid Res., 2004, 45, 2361-7.
20. Smart, E.J., De Rose, R.A., Farber, S.A. Annexin 2-caveolin 1 complex is a target of ezetimibe and regulates intestinal cholesterol transport. Proc. Natl. Acad. Sci., USA, 2004, 101(10), 3450-3455.
21. Davis, H.R., Compton, D.S., Hoos, L. Ezetimibe (SCH58235) localizes to the brush border of small intestinal enterocyte and inhibits enterocyte cholesterol uptake and absorption. Eur. Heart J., 2000, 21(suppl.), 636. Abstract P3500.
22. Ghosal, A., Hapangama, N., Yuan, Y., Achanfuo-Yeboah, J., Iannucci, R., Chowdhury, S., et al. Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of ezetimibe (Zetia). Drug Metab. Dispos., 2004, 32(3), 314-320.
23. van Heek, M., Farley, C., Compton, D.S., Hoos, L., Alton, K.B., Sybertz, E.J., et al. Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663. Br. J. Pharmacol., 2000, 129, 1748-1754.
24. Catapano, A.L. Ezetimibe: a selective inhibitor of cholesterol absorption. Eur. Heart J. Suppl., 2001, 3(suppl. E), E6-E10.
25. Knopp, R.H., Bays, H., Manion, C.V. Effect of ezetimibe on serum concentrations of lipid-soluble vitamins [abstract]. Atherosclerosis, 2001, 2(suppl.), 90. Abstract P175.
26. Zetia [prescribing information]. North Wales, PA: Merck/Schering-Plough Pharmaceuticals; 2002.
27. Punwani, N., Pai, S., Bach, C. Effect of food on oral bioavailability of SCH58235 in healthy male volunteers [abstract]. AAPS Pharm. Sci., [serial online]. 1(suppl.), S486.
28. Sudhop, T., Lutjohann, D., Kodal, A., Igel, M., Tribble, D.L., Shah, S., et al. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation, 2002, 106, 1943-1948.
29. Knopp, R.H., Gitter, H., Truitt, T., Bays, H., Manion, C.V., Lipka, L.J., et al. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur. Heart J., 2003, 24, 729-741.
30. Knopp R.H. European Atherosclerosis Society Meeting, Glasgow, Scotland, 2001.
31. Davidson, M.H., McGarry, T., Bettis, R., Melani, L., Lipka, L.J., LeBeaut, A.P., et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J. Am. Coll. Cardiol., 2002, 40, 2125-34.
32. Ballantyne, C.M., Houri, J., Notarbartolo, A., Melani, L., Lipka, L.J., Suresh, R., et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia. A prospective, randomized, double-blind trial. Circulation, 2003, 107, 2409-2415.
33. Salen, G., von Bergmann, K., Lutjohann, D., Kwiterovich, P., Kane, J., Patel, S.B., et al. Ezetimibe effectively reduces plasma plant sterols in patients with sitosterolemia. Circulation, 2004, 109, 966-971.
34. Davidson, M.H. Controversy surrounding the safety of cerivastatin. Exp. Opin. Drug Saf., 2002, 1, 207-212.
35. Foley, K.A., Simpson, R.J., Jr., Crouse, J.R. 3rd, Weiss, T.W., Markson, L.E., Alexander, C.M. Effectiveness of statin titration on low-density lipoprotein cholesterol goal attainment in patients at high risk of atherogenic events. Am. J. Cardiol., 2003, 92, 79-81.
36. Davidson, M.H., Toth, P.P. Comparative effects of lip-lowering therapies. Prog. Cardiovasc. Dis., 2004, 47, 73-104.
37. Davidson, M.H., Toth, P.P. Combination therapy in the management of complex dyslipidemias. Curr. Opin. Lipidol., 2004, 15, 423-431.
38. Davidson, M.H., McGarry, T., Bettis, R., Melani, L., Lipka, L.J., Lebeaut, A.P., et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J. Am. Coll. Cardiol., 2002, 40(12), 2125-2134.
39. Bays, H.E., Ose, L., Fraser, N., Quinto, K.L. Ezetimibe/Simvastatin Therapy Is More Effective Than Simvastatin Alone at Reducing Remnant-Like Particle Cholesterol. Abstract 1084-179, American College of Cardiology Meeting, New Orleans, Louisiana, 2004.
40. Toth, P.P. New Insights into the Treatment of Dyslipidemia: A Focus on Cardiovascular Event Reduction and the Antiatherosclerotic Effects of Atorvastatin. Curr. Atheroscler. Rep., 2005, 7, 335-343.
41. Ballantyne, C.M., Blazing, M.A., King, T.R., Brady, W.E. Efficacy of ezetimibe coadministered with simvastatin versus atorvastatin in patients with hypercholesterolemia. J. Amer. Coll. Cardiol., 2004, 43, A480-A481.
42. Ballantyne, C.M., Blazing, M.A., King, T.R., Brady, W.E., Palmisano, J. Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia. Am. J. Cardiol., 2004, 93(12), 1487-1494.
43. Feldman, T., Koren, M., Insull, W. Jr., McKenney, J., Schrott, H., Lewin, A., et al. Treatment of high-risk patients with ezetimibe plus simvastatin co-administration versus simvastatin alone to attain National Cholesterol Education Program Adult Treatment Panel III low-density lipoprotein cholesterol goals. Am. J. Cardiol., 2004, 93(12), 1481-1486.
44. Ridker, P.M., Bassuk, S.S., Toth, P.P. C-Reactive protein and risk of cardiovascular disease: evidence and clinical application. Curr. Atheroscler. Rep. 2003, 5, 341-349.
45. Libby, P., Ridker, P.M. Inflammation and atherosclerosis: role of C-reactive protein in risk assessment. Am. J. Med. 2004, 116 (Suppl. 6A), 9S-16S.
46. Ridker, P.M., Buring, J.E., Cook, N.R., Rafai, N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation, 2003, 107(3), 391-7.
47. Ridker, P.M. High-sensitivity C-reactive protein, inflammation, and cardiovascular risk: from concept to clinical practice to clinical benefit. Am. Heart J. 2004, 148(Suppl.), S19-26.
48. Sager, P.T., Capece, R., Lipka, L., Strony, J., Yang, B., Suresh R., et al. Effects of ezetimibe coadministered with simvastatin on C-reactive protein in a large cohort of hypercholesterolemic patients. Atherosclerosis, 2005, 179, 361-367.
49. Nissen, S.E., Tuzcu, E.M., Schoenhagen, P., Crowe, T., Sasiela, W.J., Tsai, J., et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N. Engl. J. Med., 2005, 352(1), 29-38.
50. Ridker, P.M., Cannon, C.P., Morrow, D., Rifai, N., Rose, L.M., McCabe, C.H., et al. C-reactive protein levels and outcomes after statin therapy. N. Engl. J. Med., 2005, 352(1), 20-8.
51. Goldstein, J.L., Brown, M.S. Familial Hypercholesterolemia. In Stanburg, J.B., Wyngaarden, J.B., Fredrickson, D.S., eds. The Metabolic Basis of Inherited Disease, 7th ed. New York, NY: McGraw-Hill, 1992, 1215-1250.
52. Gagne, C., Gaudet, D., Bruckert, E.; Ezetimibe Study Group. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation, 2002, 105(21), 2469-2475.